FluroTech Announces September and Q3 2019 Revenue

CALGARY, Alberta, Oct. 23, 2019 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), (“FluroTech” or the “Company”), a technology company focused on the analytical cannabis and hemp testing market, is pleased to announce five unit sales which generated revenue of $116,548 in September, the end of FluroTech’s third quarter of 2019. With the commercialization of the CompleTest^TM, the Company continues to ramp up sales efforts through expansion of the sales team, ongoing negotiations with distributors in the United States, and the launch of a referral program with industry participants possessing demonstrated national and international reach.

“I’m pleased with the market acceptance and proof of concept of the CompleTest^TM. We have a number of potential sales in the pipeline and expect quarterly growth in sales as numerous strategies are underway which are likely to expand the Company’s market reach and penetration,” stated Danny Dalla-Longa Chief Executive Officer. “New products which allow for further differentiation from competitors of the CompleTest^TM are anticipated to be launched in Q4.  We are excited about the future potential of FluroTech.”

Currently, FluroTech’s sales and marketing team is validating the cadmium testing protocol designed by the scientific development team and are preparing for its introduction to the market. The cadmium test is the first of four heavy metal tests which will also include mercury, lead and arsenic.

About FluroTech (TSX-V: TEST) (OTCQB: FLURF)

FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples. Using the technology that was developed at the University of Calgary, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.

To learn more, visit www.FluroTech.com.

Contact Information

Danny Dalla-Longa
Chief Executive Officer
403.680.0644
[email protected]

FluroTech Ltd.
7 – 3535 Research Road NW
Calgary, AB T2L 2K8
[email protected]

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the benefits to be realized from the Research License, the release of a low THCA testing protocol for hemp and the timing thereof, the release of a cadmium testing protocol and the timing thereof and the benefits of such additional product lines.

The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the need and demand for the CompleTest^TM and biotracker technology in the cannabis and hemp industry and the potential uses of the biotracker technology, the market for a low THCA testing protocol for hemp and the market for cadmium testing, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to, adverse market conditions and regulatory and other risks associated with the cannabis and hemp industries in general, users of the Company’s the CompleTest™ failing to achieve the anticipated benefits of the product, competition from other developers of similar technology , failure to reach commercialization of the technology, failure to realize the anticipated benefits from the Research License, a lack of demand for low THCA and cadmium testing

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.